Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genfar SA

Division of Sanofi
www.genfar.com

Latest From Genfar SA

Sanofi CSO David-Alexandre Gros On The Next Wave Of Growth In Emerging Markets: An Interview With PharmAsia News

During a visit to Shanghai, Sanofi’s chief strategy officer sits down to talk about the company’s playbook for emerging markets, which focuses on both the BRIC countries and up-and-coming markets like Vietnam, Colombia and Nigeria.

BioPharmaceutical China

Biopharma Dealmaking Quarterly Statistics, Q4 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, November 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Emerging Markets Earnings Round Up: Sanofi And BMS (Part 6)

Sanofi sees China sales dip slightly in Q3, but expects sales to rebound in the next few quarters as it sets its sights on other emerging markets such as Vietnam and Africa. Bristol Myers Squibb piggybacks on brands like Baraclude and Orencia to grow deeper in China and greater Asia.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • South America
      • Colombia
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Mario Molano, Pres.
  • Contact Info
  • Genfar SA
    Phone: 571 368 0077
    Calle 20 A # 44 - 70
    Bogota,
    Colombia
Advertisement
Advertisement
UsernamePublicRestriction

Register